Erasca (ERAS)

Erasca on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.

Download CSV

37.0M

Short interest

settlement 2026-10-15

6.3

Days to cover

-0.5 days vs prior

50.5%

Short share of volume

2026-11-02

47,980

Fails to deliver

settlement 2026-10-09

Wed 11 Nov

Next earnings

estimated date

Insider flow, 90 days

0 buys, 0 sells

As of 2026-11-02.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in ERAS is 36,963,404 shares, up 3,927,265 shares over the last month. Over the last 48 readings it ranged from 16,144,526 shares (15 October 2025) to 36,963,404 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 5.8M shares a day that is 6.3 days to cover.

Embed this chart.The embed keeps its attribution line.

<iframe src="https://xoomar.com/embed/stocks/eras" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

Preview Dark previewAdd ?theme=dark to the src for a dark chart.

Settlement	Shares short	Change	Avg daily volume	Days to cover
2026-10-15	36,963,404	+4.6%	5,817,191	6.35
2026-09-30	35,338,107	+7.0%	5,143,537	6.87
2026-09-15	33,036,139	+5.8%	4,316,648	7.65
2026-08-31	31,238,099	+1.3%	3,308,858	9.44
2026-08-14	30,847,289	+3.0%	3,080,346	10.01
2026-07-31	29,953,849	-2.6%	4,119,030	7.27
2026-07-15	30,766,629	-4.8%	5,230,546	5.88
2026-06-30	32,321,195	+2.6%	7,192,412	4.49
2026-06-15	31,493,422	-1.3%	5,461,564	5.77
2026-05-29	31,891,428	+1.5%	4,255,264	7.49
2026-05-15	31,425,335	-2.0%	4,670,591	6.73
2026-04-30	32,056,721	-5.7%	13,406,503	2.39
2026-04-15	33,974,829	+13.7%	5,601,062	6.07
2026-03-31	29,886,446	+13.5%	6,167,248	4.85
2026-03-13	26,340,417	-3.5%	4,807,956	5.48
2026-02-27	27,299,791	-3.6%	3,092,809	8.83
2026-02-13	28,314,016	+10.4%	4,463,627	6.34
2026-01-30	25,640,846	-3.7%	7,169,080	3.58
2026-01-15	26,637,035	+30.0%	12,081,005	2.20
2025-12-31	20,487,523	+20.8%	2,652,389	7.72
2025-12-15	16,962,442	+3.6%	2,394,640	7.08
2025-11-28	16,365,359	+0.7%	1,844,303	8.87
2025-11-14	16,250,251	-0.7%	1,480,911	10.97
2025-10-31	16,357,077	+1.3%	1,077,478	15.18
2025-10-15	16,144,526	-6.0%	2,880,149	5.61
2025-09-30	17,179,445	-7.7%	1,766,023	9.73
2025-09-15	18,621,402	-0.5%	1,282,505	14.52
2025-08-29	18,717,661	-0.5%	651,450	28.73
2025-08-15	18,808,653	-1.3%	699,420	26.89
2025-07-31	19,057,191	-3.6%	892,253	21.36
2025-07-15	19,770,369	+3.0%	929,902	21.26
2025-06-30	19,194,753	-8.4%	1,289,318	14.89
2025-06-13	20,956,369	-2.5%	1,523,332	13.76
2025-05-30	21,502,410	+2.4%	1,633,591	13.16
2025-05-15	20,989,573	-3.8%	1,321,027	15.89
2025-04-30	21,825,024	-7.2%	1,396,930	15.62
2025-04-15	23,517,886	-13.6%	2,287,039	10.28
2025-03-31	27,218,862	-17.8%	2,104,731	12.93
2025-03-14	33,096,383	-2.3%	1,372,894	24.11
2025-02-28	33,860,840	-1.9%	1,046,747	32.35
2025-02-14	34,521,335	+2.3%	1,521,802	22.68
2025-01-31	33,756,338	+1.8%	1,240,334	27.22
2025-01-15	33,146,761	+1.1%	1,428,095	23.21
2024-12-31	32,794,313	+3.9%	1,333,600	24.59
2024-12-13	31,561,193	-2.1%	1,363,319	23.15
2024-11-29	32,227,599	+0.3%	1,146,299	28.11
2024-11-15	32,148,765	-2.5%	1,779,191	18.07
2024-10-31	32,969,981	-2.2%	1,421,326	23.20

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 2 November 2026, the short share of ERAS volume is 50.5%, down 15.1 points over the last five sessions. Over the last 30 readings it ranged from 37.5% (15 October 2026) to 84.1% (9 October 2026). The latest reading is 8.6 points below the 30-session average of 59.1%, on 1.9M shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-11-02	966K	1.9M	50.5%	17,698
2026-10-30	822K	1.3M	61.3%	5,000
2026-10-29	378K	944K	40.0%	1,545
2026-10-28	817K	1.4M	60.0%	1
2026-10-27	1.3M	2.0M	64.7%	0
2026-10-26	1.9M	3.0M	65.6%	5,203
2026-10-23	803K	1.4M	59.1%	2,666
2026-10-22	385K	733K	52.5%	507
2026-10-21	722K	1.3M	55.6%	161
2026-10-20	799K	1.4M	55.5%	7,818
2026-10-19	914K	1.4M	64.5%	18,186
2026-10-16	1.5M	2.9M	50.4%	11,231
2026-10-15	1.8M	4.8M	37.5%	12,394
2026-10-14	768K	1.5M	49.7%	419
2026-10-13	943K	2.3M	40.4%	0
2026-10-12	965K	1.3M	76.2%	0
2026-10-09	2.6M	3.1M	84.1%	38,735
2026-10-08	1.8M	3.1M	60.5%	22,363
2026-10-07	753K	1.4M	55.3%	0
2026-10-06	1.0M	2.1M	51.0%	139
2026-10-05	1.4M	2.3M	60.3%	5,380
2026-10-02	1.0M	1.4M	71.6%	11,890
2026-10-01	990K	1.4M	72.0%	100
2026-09-30	979K	1.6M	62.8%	118
2026-09-29	1.0M	1.3M	80.7%	9,464
2026-09-28	1.0M	1.7M	58.8%	50
2026-09-25	727K	1.2M	61.1%	124
2026-09-24	1.4M	2.4M	56.7%	13,484
2026-09-23	773K	1.6M	47.3%	23,693
2026-09-22	691K	1.0M	66.5%	5,665

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 9 October 2026, the fails-to-deliver balance in ERAS is 47,980 shares, up 45,825 shares over the last settlement date. Over the last 30 readings it ranged from 7 shares (28 July 2026) to 910,462 shares (22 June 2026). The latest reading sits at the bottom of that range.

Settlement	Shares failed	Price	Value
2026-10-09	47,980	$15.46	$742K
2026-10-08	2,155	$14.12	$30K
2026-10-06	27,719	$14.72	$408K
2026-10-01	109,199	$14.66	$1.6M
2026-09-30	96,260	$14.21	$1.4M
2026-09-29	111,483	$14.13	$1.6M
2026-09-08	524	$16.19	$8K
2026-08-27	1,809	$19.15	$35K
2026-08-12	4,850	$18.31	$89K
2026-08-11	99,965	$18.12	$1.8M
2026-07-30	902	$17.72	$16K
2026-07-29	90	$18.16	$2K
2026-07-28	7	$18.87	$132
2026-07-24	139,616	$19.34	$2.7M
2026-07-22	458	$19.38	$9K
2026-07-17	158	$19.02	$3K
2026-07-16	132	$21.26	$3K
2026-07-09	202,044	$18.87	$3.8M
2026-07-07	260,992	$18.85	$4.9M
2026-07-02	3,339	$17.92	$60K
2026-06-29	102,553	$16.01	$1.6M
2026-06-26	3,388	$14.95	$51K
2026-06-22	910,462	$13.67	$12.4M
2026-06-18	1,379	$13.98	$19K
2026-06-15	668	$14.05	$9K
2026-06-11	473	$13.37	$6K
2026-06-01	86,689	$12.84	$1.1M
2026-05-20	10,320	$10.32	$107K
2026-05-19	2,629	$10.27	$27K
2026-05-12	30	$10.44	$313

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for ERAS in the last 90 days. The most recent filings are listed below. Latest filing: Garner Ebun (Chief Legal Officer) on 2026-04-01.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2026-04-01	Garner Ebun	Chief Legal Officer	Sell	80K	$16.40	$1.3M	25K
2026-04-01	Garner Ebun	Chief Legal Officer	Exercise or conversion	80K	$1.70	$136K	105K
2026-03-04	Morris Shannon	Chief Medical Officer	Sell	20K	$15.04	$301K	0
2026-03-04	Morris Shannon	Chief Medical Officer	Exercise or conversion	20K	$1.70	$34K	20K
2026-01-07	Garner Ebun	General Counsel & Corp. Sec.	Sell	120K	$5.59	$671K	25K
2026-01-07	Garner Ebun	General Counsel & Corp. Sec.	Exercise or conversion	120K	$1.70	$204K	145K
2025-12-15	Garner Ebun	General Counsel & Corp. Sec.	Grant	4K	$1.19	$5K	25K
2025-12-15	Chacko David M.	CFO and CBO	Other transaction	18K	$1.19	$21K	280K
2025-05-23	Multani Pratik S	Director	Gift	6K	$0.00	$0	167K
2025-05-23	Multani Pratik S	Director	Gift	6K	$0.00	$0	6K
2024-12-13	Garner Ebun	General Counsel & Corp. Sec.	Other transaction	6K	$1.56	$9K	21K
2024-12-13	Chacko David M.	CFO and CBO	Other transaction	12K	$1.56	$19K	262K
2024-06-14	Garner Ebun	General Counsel & Corp. Sec.	Other transaction	6K	$1.56	$9K	21K
2024-06-14	Chacko David M.	CFO and CBO	Other transaction	3K	$1.56	$5K	262K
2024-05-21	Casdin Alexander W.	Director	Buy	80K	$2.27	$182K	574K
2023-12-15	Garner Ebun	General Counsel & Corp. Sec.	Other transaction	5K	$1.59	$9K	10K
2023-12-15	Chacko David M.	CFO and CBO	Other transaction	7K	$1.59	$12K	247K
2023-12-06	Lim Jonathan E	Chairman & CEO	Buy	278K	$1.72	$478K	12.9M
2023-12-06	Start Valerie Denise Harding	Director	Buy	10K	$1.85	$19K	20K
2023-12-05	Lim Jonathan E	Chairman & CEO	Buy	722K	$1.69	$1.2M	12.9M
2023-12-04	Casdin Alexander W.	Director	Buy	30K	$1.66	$50K	494K
2023-10-05	Lim Jonathan E	Chairman & CEO	Buy	1.0M	$2.03	$2.0M	19.5M
2023-06-08	Lim Jonathan E	Chairman & CEO	Buy	100K	$2.75	$275K	18.4M
2023-04-10	Casdin Alexander W.	Director	Buy	20K	$2.76	$55K	464K
2023-03-28	Lim Jonathan E	Chairman & CEO	Buy	100K	$2.84	$284K	18.3M
2023-02-01	Garner Ebun	General Counsel & Corp. Sec.	Other transaction	2K	$4.10	$10K	4K
2023-02-01	Garner Ebun	General Counsel & Corp. Sec.	Other transaction	2	$3.89	$8	4K
2023-02-01	Wei Lin	Chief Medical Officer	Other transaction	2K	$4.10	$7K	316K
2023-02-01	Wei Lin	Chief Medical Officer	Other transaction	2	$3.89	$8	316K
2023-02-01	Chacko David M.	Chief Financial Officer	Other transaction	2	$3.89	$8	239K
2023-02-01	Chacko David M.	Chief Financial Officer	Other transaction	2K	$4.10	$7K	239K
2023-01-10	Lim Jonathan E	Chairman & CEO	Buy	60K	$3.86	$232K	20.3M
2022-12-21	Bristol James Arthur	Director	Buy	20K	$4.14	$83K	20K
2022-12-21	Start Valerie Denise Harding	Director	Buy	10K	$4.64	$46K	10K
2022-12-15	Casdin Alexander W.	Director	Buy	20K	$4.87	$97K	444K
2022-12-14	Lim Jonathan E	Chairman & CEO	Buy	40K	$4.99	$200K	20.2M
2022-12-13	Cormorant Asset Management, LP	Director	Buy	308K	$6.50	$2.0M	10.8M
2022-07-01	Casdin Alexander W.	Director	Other transaction	750K	$0.00	$0	0
2022-02-01	Chacko David M.	Chief Financial Officer	Other transaction	2K	$11.60	$18K	237K
2022-02-01	Wei Lin	Chief Medical Officer	Other transaction	2K	$11.60	$18K	314K
2022-02-01	Garner Ebun	General Counsel & Corp. Sec.	Other transaction	990	$11.60	$11K	2K
2021-08-10	Chen Bihua	Director	Buy	200K	$22.10	$4.4M	10.5M
2021-07-26	Chen Bihua	Director	Sell	200K	$18.77	$3.8M	10.3M
2021-07-20	Hambleton Julie	Director	Buy	6K	$16.00	$96K	6K
2021-07-20	Multani Pratik S	Director	Buy	6K	$16.00	$99K	173K
2021-07-20	Start Valerie Denise Harding	Director	Buy	2K	$16.00	$32K	2K
2021-07-20	Burow Kristina	TenPercentOwner	Conversion	5.5M	price not stated in the filing	not stated	5.5M
2021-07-20	Casdin Alexander W.	Director	Conversion	150K	price not stated in the filing	not stated	338K
2021-07-20	Casdin Alexander W.	Director	Conversion	750K	price not stated in the filing	not stated	750K
2021-07-20	Garner Ebun	General Counsel	Buy	900	$16.00	$14K	900
2021-07-20	City Hill, LLC	TenPercentOwner	Conversion	5.1M	price not stated in the filing	not stated	20.2M
2021-07-20	City Hill, LLC	TenPercentOwner	Conversion	5.4M	price not stated in the filing	not stated	11.9M
2021-07-20	Cormorant Asset Management, LP	TenPercentOwner	Buy	950K	$16.00	$15.2M	10.5M
2021-07-20	Cormorant Asset Management, LP	TenPercentOwner	Conversion	9.6M	price not stated in the filing	not stated	9.6M

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Planned sales (Form 144)

Newest first. JSON

10 Form 144 notices on file for ERAS worth $2.7M at the prices reported; 0 in the last 90 days worth $0. Latest: Ebun Garner filed on 2026-04-01 to sell 80,000 shares ($1.3M) from 2026-04-01.

Filed	Seller	Shares	Market value	Of outstanding	Sale from	Broker
2026-04-01	Ebun GarnerOfficer	80K	$1.3M	0.026%	2026-04-01	Merrill Lynch
2026-03-16	Erasca FoundationFoundation	8K	$117K	0.003%	2026-03-16	Merrill Lynch
2026-03-04	Shannon MorrisOfficer	20K	$301K	0.007%	2026-03-04	Merrill Lynch
2026-02-17	Erasca FoundationFoundation	8K	$99K	0.003%	2026-02-17	Merrill Lynch
2026-01-15	Erasca FoundationFoundation	8K	$69K	0.003%	2026-01-15	Merrill Lynch
2026-01-07	Ebun GarnerOfficer	120K	$671K	0.042%	2026-01-07	Merrill Lynch
2025-12-15	Erasca FoundationFoundation	8K	$30K	0.003%	2025-12-15	Merrill Lynch
2025-11-17	Erasca FoundationErasca Foundation	8K	$22K	0.003%	2025-11-17	Merrill Lynch
2025-10-15	Erasca FoundationErasca Foundation	8K	$21K	0.003%	2025-10-15	Merrill Lynch
2025-09-15	Erasca FoundationErasca Foundation	8K	$13K	0.003%	2025-09-15	Merrill Lynch

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

12 holders report 5% or more of ERAS in their latest filing, all on Schedule 13G (passive). The largest reported stake is Jonathan E. Lim at 10.4% of the class (36,968,486 shares), filed 2026-08-14 for an event on 2026-06-30.

Filed	Form	Holder	Shares	Of class	Event
2026-08-14	13G/Ano. 4	Jonathan E. Limindividual	37.0M	10.4%	2026-06-30
2026-08-14	13G/Ano. 4	Conyee T. Limindividual	19.5M	5.6%	2026-06-30
2026-08-14	13G/Ano. 4	City Hill, LLCother entity	12.9M	3.7%	2026-06-30
2026-05-15	13G/Ano. 3	T. Rowe Price Investment Management, Inc.investment adviser	21.2M	6.8%	2026-03-31
2026-05-15	13G/Ano. 1	Nimish Shahindividual	16.4M	5.3%	2026-03-31
2026-05-15	13G/Ano. 1	Venrock Healthcare Capital Partners III, L.P.partnership	16.4M	5.3%	2026-03-31
2026-05-15	13G/Ano. 1	VHCP Co-Investment Holdings III, LLCother entity	16.4M	5.3%	2026-03-31
2026-05-15	13G/Ano. 1	Venrock Healthcare Capital Partners EG, L.P.partnership	16.4M	5.3%	2026-03-31
2026-05-15	13G/Ano. 1	VHCP Management III, LLCother entity	16.4M	5.3%	2026-03-31
2026-05-15	13G/Ano. 1	VHCP Management EG, LLCother entity	16.4M	5.3%	2026-03-31
2026-05-15	13G/Ano. 1	Bong Y. Kohindividual	16.4M	5.3%	2026-03-31
2026-05-15	13G	RTW Investments, LPinvestment adviser, partnership	16.2M	5.2%	2026-03-31
2026-05-15	13G	Roderick Wongparent holding company, individual	16.2M	5.2%	2026-03-31
2026-05-15	13G/Ano. 1	Paradigm BioCapital Advisors LPpartnership	10.4M	3.3%	2026-03-31
2026-05-15	13G/Ano. 1	Senai Asefaw, M.D.individual	10.4M	3.3%	2026-03-31
2026-05-15	13G/Ano. 1	Paradigm BioCapital Advisors GP LLCother entity	10.4M	3.3%	2026-03-31
2026-05-15	13G/Ano. 1	Paradigm BioCapital International Fund Ltd.corporation	9.2M	2.9%	2026-03-31
2026-05-12	13G/Ano. 1	Suvretta Capital Management, LLCinvestment adviser, other entity	3.4M	1.1%	2026-03-31
2026-05-12	13G/Ano. 1	Aaron Cowenparent holding company, individual	3.4M	1.1%	2026-03-31
2026-05-12	13G/Ano. 1	Averill Master Fund, Ltd.corporation	2.9M	0.9%	2026-03-31
2025-11-14	13G/Ano. 1	Logos Global Management GP LLCparent holding company, other entity	13.6M	4.8%	2025-09-30
2025-11-14	13G/Ano. 1	Logos Global Management LPinvestment adviser, partnership	13.6M	4.8%	2025-09-30
2025-11-14	13G/Ano. 1	Arsani Williamparent holding company, individual	13.6M	4.8%	2025-09-30

13F holders

Tracked managers holding ERAS at their latest 13F. JSON

7 of the 30 tracked managers held ERAS at their latest 13F, $96.9M in total at quarter-end prices. Renaissance Technologies is the largest at $25.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.

Fund	Quarter	Shares	Value	Of portfolio	Change in shares
Renaissance Technologies	2026-06-30	1.4M	$25.1M	0.03%	-30K
Point72 Asset Management	2026-06-30	1.2M	$22.8M	0.03%	+554K
D. E. Shaw & Co.	2026-06-30	950K	$17.4M	0.01%	-270K
Millennium Management	2026-06-30	910K	$16.7M	0.01%	+334K
AQR Capital Management	2026-06-30	681K	$12.5M	0.00%	-10K
Citadel Advisors	2026-06-30	95K	$1.7M	0.00%	-404K
Two Sigma Investments	2026-06-30	36K	$657K	0.00%	+20K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In FY 2025 it generated -$95.5M of operating cash flow.

Cash: $42.5M
Equity: $361.9M
Total assets: $435.1M
Shares outstanding: 349,762,035

Quarterly, last 8 quarters

Quarter	Period end	Revenue	Net income	Margin	Diluted EPS
Q2 FY 2026	2026-06-30	n/a	-$44.1M	n/a	-0.14
Q1 FY 2026	2026-03-31	n/a	-$183.4M	n/a	-0.60
Q4 FY 2025derived	2025-12-31	n/a	-$29.1M	n/a	n/a
Q3 FY 2025	2025-09-30	n/a	-$30.6M	n/a	-0.11
Q2 FY 2025	2025-06-30	n/a	-$33.9M	n/a	-0.12
Q1 FY 2025	2025-03-31	n/a	-$31.0M	n/a	-0.11
Q4 FY 2024derived	2024-12-31	n/a	-$32.2M	n/a	n/a
Q3 FY 2024	2024-09-30	n/a	-$31.2M	n/a	-0.11

Fiscal years, with buybacks and dividends

Fiscal year	Ends	Revenue	Net income	Operating cash flow	Capex	Buybacks	Dividends
FY 2025	2025-12-31	n/a	-$124.5M	-$95.5M	$128K	n/a	n/a
FY 2024	2024-12-31	n/a	-$161.7M	-$109.4M	$60K	n/a	n/a
FY 2023	2023-12-31	n/a	-$125.0M	-$101.2M	$1.8M	n/a	n/a
FY 2022	2022-12-31	n/a	-$242.8M	-$103.3M	$14.6M	n/a	n/a
FY 2021	2021-12-31	n/a	-$122.8M	-$79.6M	$11.2M	n/a	n/a

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-04 from the cover page.

What this page is

Erasca in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Erasca (ERAS), SEC CIK 1761918, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest: FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
Fails to deliver: SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
Planned sales: SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-04-01.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
13F holders: SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Financials: SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
Earnings dates: SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-04-01.JSON and CSV
Company record: EDGAR filing index for CIK 1761918Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as pharmaceutical preparations

Other company pages

Datasets

Frequently Asked Questions

How much of ERAS is sold short?

36,963,404 shares were held short at the 2026-10-15 settlement, 6.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.

What is ERAS's daily short volume?

On 2026-11-02, 965,746 of the 1,912,375 ERAS shares reported to FINRA were sold short, 50.5% of the day's reported volume. Short volume is a flow for one day, not a position.

Does ERAS have fails to deliver?

The SEC's latest file shows 47,980 ERAS shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.

Are ERAS insiders buying or selling?

No open-market insider trades were reported for ERAS in the last 90 days. The most recent filings are listed below. Latest filing: Garner Ebun (Chief Legal Officer) on 2026-04-01.

Have ERAS insiders filed to sell?

10 Form 144 notices on file for ERAS worth $2.7M at the prices reported; 0 in the last 90 days worth $0. Latest: Ebun Garner filed on 2026-04-01 to sell 80,000 shares ($1.3M) from 2026-04-01.

Who owns 5% or more of ERAS?

What did ERAS report last quarter?

In FY 2025 it generated -$95.5M of operating cash flow.

Which tracked 13F managers own ERAS?

7 of the 30 tracked 13F managers held ERAS shares at their latest filing, $96.9M in all. The largest: Renaissance Technologies (1.4M shares, $25.1M), Steve Cohen's Point72 Asset Management (1.2M shares, $22.8M), D. E. Shaw & Co. (950K shares, $17.4M), Izzy Englander's Millennium Management (910K shares, $16.7M), Cliff Asness's AQR Capital Management (681K shares, $12.5M), Ken Griffin's Citadel Advisors (95K shares, $1.7M). The table above lists all 7.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.